Istiratumab  (Synonyms: MM 141; MM-005)

Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IGF1R & ERBB3

Istiratumab (500 nM, 24 h) inhibits AKT activation in response to IGF-1 and HRG costimulation in human pancreatic cancer cell lines^[2].
Istiratumab (500 nM, 24 h) inhibits IGF-1- and HRG-induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS mutations^[2].
Istiratumab (500 nM, 24 h) induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway^[2].
Istiratumab (1 μM, 60 min) block activation of the PI3K and MAPK signaling cascades in ovarian cancer cell lines^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3480  [NCBI] & 2065  [NCBI]

P08069 & P21860

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

199.63 kDa

1509928-04-4

Liquid

Colorless to light yellow

[Istiratumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-lambda]2

• 
  Flow cytometric analysis of 1×10⁶ MCF-7 cells labelling ERBB3 (red) with Istiratumab (HY-P99672). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.

• [1]. Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87.  [Content Brief]

  [2]. Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885.  [Content Brief]

  [3]. Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832.  [Content Brief]